Wilks Brothers’s Bristol-Myers Squibb BMY Stock Holding History

Wilks Brothers’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-16,400	Closed	-$908K	–	58
2018 Q2	$908K	Buy	+16,400	New	+$886K	0.1%	71

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wilks Brothers's BMY Position: Q3 2018 in Review

Wilks Brothers sold out of Bristol-Myers Squibb (BMY) in Q3 2018, closing a stake of 16,400 shares — an estimated $908K sold.

Wilks Brothers first reported a position in BMY in Q2 2018 and held it in 1 quarter. The position peaked at $908K in Q2 2018. 1,730 funds tracked by Wall St. Rank hold BMY as of Q3 2018.

Wilks Brothers reported no remaining Bristol-Myers Squibb position as of Q3 2018 after selling out during the quarter.
Wilks Brothers sold 16,400 Bristol-Myers Squibb shares in Q3 2018, an estimated $908K.
Wilks Brothers first reported a position in Bristol-Myers Squibb in Q2 2018 and held it in 1 quarter.
Wilks Brothers's Bristol-Myers Squibb position peaked at $908K in Q2 2018.
1,730 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2018.

Based on Wilks Brothers's 13F filing for Q3 2018, filed 9 Nov 2018.